Study wrapper · #1022
Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder - A narrative review of available clinical evidence.
Klausen MK, Fink-Jensen A Biological psychiatry. 2026.
DOI: 10.1016/j.biopsych.2026.07.010PubMed: 42486217
Editor's note
A narrative review synthesizing randomized, observational, and preclinical evidence on GLP-1 receptor agonists and alcohol use disorder. Only three randomized trials exist so far, and while observational data consistently point in the same direction, the authors are clear that larger long-term trials are still needed. Semaglutide is named as a leading candidate, though much of the evidence spans the drug class rather than one agent.
Plain-language abstract
This review summarizes evidence that GLP-1 receptor agonists, including semaglutide, are associated with reduced alcohol consumption and craving in people with alcohol use disorder. The strongest findings come from a small number of randomized trials plus larger observational datasets.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026